MetaCap

aTyr Pharma (ATYR) vs BioStem Technologies (BSEM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

aTyr Pharma (ATYR) has outperformed BioStem Technologies (BSEM) over the past year, gaining 474.4% versus a loss of 84.0%. Over five years, ATYR leads with a -52.6% price change compared with -55.9% for BSEM. BioStem Technologies is the larger company by market cap ($12.2 million vs $9.7 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATYR+474.44%BSEM-83.98%
+1096%+478%-140%
Nov 21, 20251 yearNov 20, 2026
ATYR-53.41%BSEM-25.28%
+2716%+1242%-232%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATYR versus BSEM key metrics
MetricATYRBSEM
Share price$3.82$0.6351
Market cap$9.74M$12.18M
1-day change+3.52%-10.23%
YTD return+387.87%-83.33%
1-year return+474.44%-83.98%
5-year return-52.61%-55.90%
P/E ratio (TTM)—0.72
Forward P/E—2.19
EPS (TTM)$-21.64$0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$190.00K—
Revenue growth (YoY)-19.15%—
Net income (latest FY)$-74.12M—
Operating margin-40856.32%—
Net margin-39009.47%—
52-week high$44.40$8.40
52-week low$3.69$0.5347
Distance from 52-week high-91.40%-92.44%
Analyst consensusbuynone
Avg. price target upside-25.13%+1002.19%
Average volume115.38K194.93K
Shares outstanding2.55M19.18M
Employees5873
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATYR has outperformed BSEM by 558.4 percentage points over the past year.

About aTyr Pharma

ATYR stock →

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

ATYR vs BSEM FAQ

Which is bigger, aTyr Pharma or BioStem Technologies?

BioStem Technologies (BSEM) is larger, with a market capitalization of $12.18M compared with $9.74M for aTyr Pharma (ATYR).

Which stock has performed better over the past year, ATYR or BSEM?

ATYR returned +474.44% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.

Are aTyr Pharma and BioStem Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons